Finger on the Pulse
In favor of micropulse transscleral cyclophotocoagulation for glaucoma mild – and wild
Nir Shoham-Hazon | | Longer Read
At a Glance
- Micropulse transscleral cyclophotocoagulation (MP-TSCPC) has proven to be a safe, effective and reliable approach for lowering IOP
- Unlike other interventions, MP-TSCPC delivers energy in a 31.3 percent duty cycle, allowing tissue to cool between each application, so there is minimal impact on target tissue and a reduced risk of injury to adjacent ocular tissue
- MP-TSCPC can be used early in the disease course and requires minimal medication, reducing the reliance on anti-inflammatory drops post-procedure
- It can also be used on a wide range of glaucoma severity, not just those in the most advanced stages of disease progression.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.